Related Experiment Video
Updated: Dec 17, 2025

Whole-Body Nanoparticle Aerosol Inhalation Exposures
Published on: May 7, 2013
Pathological effects of nano-sized particles on the respiratory system
1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Abstract:
Recent advances in nanotechnology have made significant progress in biomedical sciences. However, there are growing concerns that exposure to naturally-occurring and synthetic nano-sized particles promotes various types of human diseases. The lungs are the vital organ for gas exchange. Due to their unique position, the lungs can be the primary route that nanoparticles (NPs) enter the human body, which exerts toxic effects. In spite of the wide applications of NPs, the precise effects on health following exposure are not fully understood. To address this, the biophysical properties of naturally-occurring and synthetic NPs, their pathological effects on the respiratory system and the potential human health risk are examined. The goal of this review is to provide the current evidence that exposure to NPs is a risk factor to develop human diseases. The understanding of the pathological process by NPs is essential in preventing and the treatment of nanoparticle-induced human diseases.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Factors Affecting Pulmonary Ventilation
Alveolar Surface Tension
The alveolar fluid lines the luminal surface of the alveoli and exerts a force called surface tension. This force is caused by the polar water molecules in the liquid being more strongly attracted to each...
Pneumonia II: Pathophysiology
Other Pulmonary Disorders
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...

